Aurolab

Madurai, India Founded: 1992 • Age: 34 yrs Listed
Manufacturer of high quality ophthalmic consumables
Request Access
Report Incorrect Data
Page last updated

About Aurolab

Aurolab is a publicly listed company based in Madurai (India) founded in 1992 by Bala Krishnan. Manufacturer of high quality ophthalmic consumables. Its Indian entity Auro Laboratories Limited reported revenue of ₹32.75 Cr. Aurolab offers products and services including Intraocular Lenses (IOLs), Diagnostic Equipment, Surgical Devices, and Ophthalmic Therapeutics. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy.

Company details

Aurolab, an integral part of the Aravind Eye Care System manufactures high quality ophthalmic consumables such as intra-ocular lenses, surgical sutures, pharmaceutical products, surgical blades and equipments. Its products are exported to 130 countries worldwide, with focus markets like India, Africa, Latin America, Central America and Southeast Asia. The company has altered the eye-care industry by bringing down the price of the intra-ocular lens down to a tenth of international prices in the late 1990s and grown to market its products across 130 countries.

Operational Areas
Healthcare → Ophthalmology
Key Metrics
  • Market Cap
    ₹140 Cr

    AUROLAB · BSE

  • Share Price
    ₹228.90

    +1.82% today

  • Revenue
    ₹30.74 Cr

    FY 2025-26 · +60.8% YoY

  • EBITDA
    ₹9.86 Cr

    Margin 32.1%

  • Net Profit
    ₹3.79 Cr

    FY 2025-26 · +108.2% YoY

  • P/E (TTM)
    77.0x

    P/B 3.3x

  • ROE
    7.9%

    ROCE 9.2%

  • Debt / Equity
    1.21

    Interest cover 60.3x

  • Investors
    Ideaship

Products & Services of Aurolab

Aurolab offers a comprehensive portfolio of products and services, including Intraocular Lenses (IOLs), Diagnostic Equipment, Surgical Devices, and Ophthalmic Therapeutics.

Intraocular Lenses (IOLs)
Ophthalmic Devices

Products for cataract surgery to restore vision effectively.

Diagnostic Equipment
Medical Diagnostics

Tools for optimizing insights in eye disease treatment.

Surgical Devices
Surgical Instruments

Equipment enhancing precision in ophthalmic procedures.

Ophthalmic Therapeutics
Therapeutic Solutions

Medications expanding possibilities in eye health management.

Apps and channels of Aurolab

its YouTube channel Aurolab has 2.94K subscribers and 30 videos.

Aurolab
YouTube 2.94K subscribers 30 videos Science & Technology
Open channel

Videos from Aurolab

The most watched videos on Aurolab's YouTube channel, Aurolab (2.94K subscribers). Click a video to play it here.

AUROLAB BRAND FILM
4.9K views
Aurolab National Sales Meet 2024!
906 views
Empowering Excellence: Heartfelt Greetings | Aurolab Suture 25! ​
725 views
See New Possibilities with Aurolab
651 views

More on Aurolab.

Funding Insights of Aurolab

  • Total Rounds 1
  • Investors Count 1

All 1 funding rounds of Aurolab with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2020Private Equity Round–Ideaship
–
Valuation history

1 investors in total: 1 institutional.

Investors in Aurolab

Aurolab has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Ideaship.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Ideaship
Early-stage ventures are funded by Ideaship VC fund.
ideashipfund.comPortland, United States
Premium access

Investor details for Aurolab

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Auro Laboratories Limited (Aurolab)

Auro Laboratories Limited is the primary company behind Aurolab. The board of Auro Laboratories Limited currently have 6 directors; the longest-serving is Sharat Deorah, appointed in 1989. 7 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sharat Deorah
DIN 00230784
Managing Director26 May 198937 yrs 5 moAuro Laboratories Limited
Siddhartha Deorah
DIN 00230796
Whole-time director16 Dec 201312 yrs 10 moAuro Laboratories Limited
Kavita Vijayakant Sharma
DIN 07139910
Director27 Mar 201511 yrs 7 moAuro Laboratories Limited
Kiran Suresh Kulkarni
DIN 09175595
Whole-time director24 May 20215 yrs 5 moAuro Laboratories Limited
Vishal Kailashchandra Jhunjhunwala
DIN 00359872
Director23 Aug 20233 yrs 2 moAuro Laboratories Limited
Mahendra Kumar Daga
DIN 10570354
Director01 Apr 20242 yrs 7 moAuro Laboratories Limited

People of Aurolab

18 people are tracked at Aurolab (5 in leadership, 6 in board & advisors, 7 in team).

NameRoleGroup
Bala Krishnan
Founder & Managing DirectorLeadership
Sriram Ravilla
Managing DirectorLeadership
R.D. Sriram
Managing DirectorLeadership
Venkatesa Kannan
Head, Pharmaceutical DivisionLeadership
Rajib Choudhury
Country Business HeadLeadership
R. Kim
TrusteeBoard & advisors
Govindappa Srinivasan
TrusteeBoard & advisors
R.D. Thulasiraj
TrusteeBoard & advisors
P. Namperumalsamy
TrusteeBoard & advisors
G. Natchiar
TrusteeBoard & advisors
Dr.aravind Srinivasan
SecretaryBoard & advisors
N. Vishnu Prasad
Marketing Manager, InternationalTeam
Hukkim Bazith
Senior Business Development ExecutiveTeam
Shashibhushan Yadav
Area Sales ManagerTeam
Senthilkumar Vadivelu
Key Accounts ExecutiveTeam
Antony Renny
International Marketing ManagerTeam
Pankaj Kumar
Senior Sales ExecutiveTeam
Praveen Raja
Product ManagerTeam
Premium access

Complete people profiles for Aurolab

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Aurolab

Aurolab is a publicly listed company on the BSE with ticker symbol AUROLAB in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onBSE: AUROLAB
  • Listed entityAuro Laboratories Limited
  • Exchange sectorPharmaceuticals

Financials of Aurolab

Exchange-reported figures of Auro Laboratories Limited, the listed company behind Aurolab (BSE: AUROLAB).

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹30.74 Cr
+60.8% YoY
EBITDA
₹9.86 Cr
+217.0% YoY
Profit After Tax
₹3.79 Cr
+108.2% YoY
Net Worth
₹46.35 Cr
+7.9% YoY
Total Assets
₹110 Cr
+24.9% YoY
Total Debt
₹63.31 Cr
+40.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue30.7419.1253.6452.8950.8754.2543.79
Revenue growth+60.8%-64.4%+1.4%+4.0%-6.2%+23.9%-
EBITDA9.863.1110.674.394.6211.236.27
EBITDA margin+32.1%+16.3%+19.9%+8.3%+9.1%+20.7%+14.3%
Profit before tax4.811.8610.343.453.8610.495.64
Net profit3.791.827.792.452.837.174.06
Net profit margin+12.3%+9.5%+14.5%+4.6%+5.6%+13.2%+9.3%
EPS (₹)5.672.9512.503.924.5611.526.51
Balance sheet
Total assets11087.9868.2040.6145.3031.7424.65
Net worth46.3542.9741.9634.2031.5228.5821.50
Total debt63.3145.0126.256.4113.783.163.16
Cash & bank1.670.631.652.4212.4014.545.68
Net working capital22.2011.1614.7821.9329.6119.6911.81
Cash flow
Cash from operations2.115.0218.813.28(6.59)12.829.30
Cash from investing(14.78)(23.70)(38.67)(5.08)(5.34)(3.51)(2.21)
Cash from financing14.0417.6919.09(8.18)9.79(0.46)(5.52)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8.779.839.398.842.777.403.053.10
Revenue growth (YoY)+216.6%+32.8%+207.9%+185.2%-51.6%---
Other income0.110.660.180.980.420.130.140.31
Total expenses5.466.655.336.482.746.592.612.38
EBITDA3.313.184.062.360.030.810.440.72
EBITDA margin+37.7%+32.3%+43.2%+26.7%+1.1%+10.9%+14.4%+23.2%
Depreciation0.910.900.980.650.270.290.270.27
Interest1.371.491.520.960.280.300.250.28
Profit before tax1.141.451.741.73(0.10)0.350.060.48
Tax0.080.48(0.21)1.000.00(0.04)0.020.12

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 06 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8.779.839.398.842.777.403.053.10
Revenue growth (YoY)+216.6%+32.8%+207.9%+185.2%-51.6%---
Other income0.110.660.180.980.420.130.140.31
Total expenses5.466.655.336.482.746.592.612.38
EBITDA3.313.184.062.360.030.810.440.72
EBITDA margin+37.7%+32.3%+43.2%+26.7%+1.1%+10.9%+14.4%+23.2%
Depreciation0.910.900.980.650.270.290.270.27
Interest1.371.491.520.960.280.300.250.28
Profit before tax1.141.451.741.73(0.10)0.350.060.48
Tax0.080.48(0.21)1.000.00(0.04)0.020.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue30.7419.1253.6452.8950.8754.2543.79
Revenue growth+60.8%-64.4%+1.4%+4.0%-6.2%+23.9%-
Other income2.010.931.500.941.090.760.97
Total expenses20.8816.0142.9748.5046.2543.0237.52
Employee cost5.862.473.913.763.703.643.48
EBITDA9.863.1110.674.394.6211.236.27
EBITDA margin+32.1%+16.3%+19.9%+8.3%+9.1%+20.7%+14.3%
Depreciation2.811.101.091.071.021.041.02
Interest4.251.080.740.810.830.460.58
Profit before tax4.811.8610.343.453.8610.495.64
Tax1.280.042.551.001.033.321.58
Net profit3.791.827.792.452.837.174.06
Net profit margin+12.3%+9.5%+14.5%+4.6%+5.6%+13.2%+9.3%
EPS (₹)5.672.9512.503.924.5611.526.51
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital6.236.236.236.236.236.236.23
Reserves & surplus40.1236.7435.7327.9725.2922.3515.27
Shareholders' funds (net worth)46.3542.9741.9634.2031.5228.5821.50
Secured loans58.6142.7126.186.018.131.931.81
Unsecured loans4.702.300.070.405.651.231.35
Total debt63.3145.0126.256.4113.783.163.16
Total liabilities11087.9868.2040.6145.3031.7424.65
Assets
Gross block89.1436.1036.1025.4725.3524.2823.96
Net block75.1821.0622.1512.6213.6013.5514.23
Capital work in progress14.4856.4832.687.673.680.130.12
Investments0.010.050.050.050.050.050.05
Inventories13.543.678.2411.764.252.554.06
Sundry debtors9.159.3913.3912.4013.617.305.78
Cash & bank balances1.670.631.652.4212.4014.545.68
Loans & advances6.407.187.579.087.363.772.42
Total current assets30.7620.8730.8535.6637.6228.1617.94
Total current liabilities8.569.7116.0713.738.018.476.13
Net working capital22.2011.1614.7821.9329.6119.6911.81
Total assets11087.9868.2040.6145.3031.7424.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.000.992.4212.4014.545.684.11
Net cash from operating activities2.115.0218.813.28(6.59)12.829.30
Net cash from investing activities(14.78)(23.70)(38.67)(5.08)(5.34)(3.51)(2.21)
Net cash from financing activities14.0417.6919.09(8.18)9.79(0.46)(5.52)
Net change in cash1.37(0.99)(0.77)(9.98)(2.14)8.851.58
Closing cash1.670.631.652.4212.4014.545.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+60.8%-64.4%+1.4%+4.0%-6.2%+23.9%-
EBITDA growth+217.0%-70.9%+143.1%-5.0%-58.9%+79.1%-
PBT growth+158.6%-82.0%+199.7%-10.6%-63.2%+86.0%-7.1%
Net income growth+108.2%-76.6%+218.0%-13.4%-60.5%+76.6%-
Revenue CAGR (3Y)-16.6%-27.8%-0.4%+6.5%+2.8%+10.0%+7.3%
EBITDA CAGR (3Y)+31.0%-12.4%-1.7%-11.2%-12.9%+20.9%+12.3%
Profitability & leverage
Net income margin+11.5%+9.5%+14.5%+4.6%+5.6%+13.2%+9.3%
Return on capital employed+9.2%+3.8%+20.4%+9.9%+12.2%+38.9%+24.8%
Return on net worth+7.9%+4.3%+20.5%+7.4%+9.5%+28.7%+20.8%
Debt / equity1.210.840.430.310.280.130.29
Long-term debt / equity0.860.610.270.060.070.110.29
Interest cover60.2853.737.7224.4023.064.5111.05
Efficiency & per share
Fixed asset turnover0.490.531.742.082.052.251.85
Inventory turnover3.573.215.366.6114.9616.4111.79
Debtors turnover3.321.684.164.074.878.306.13
EPS (₹)5.672.9512.503.924.5611.526.51
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)74.3668.9467.3254.8750.5845.8634.49

Timeline of Aurolab

2 dated milestones of Aurolab across 28 years, from founding to its latest funding, stage changes and deals.

  1. Founded Aurolab is founded.
  2. Funding First funding round.

Web traffic of Aurolab

The website of Aurolab (aurolab.com) receives about 4.7K visits a month.

  • Monthly visits
    4.7K

    ▲ 55.2% vs previous month

Similar websites

Websites whose visitors overlap most with Aurolab. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Accuray
accuray.com
100%
22K#1,313,331View details
PIH
pih.org
79%
105.2K#370,416View details
aurosiksha.org
aurosiksha.org
79%
#3,195,722–
Subbalakshmi Lakshmipathy College of Science
slcs.edu.in
34%
#353,470View details

Top companies in Ophthalmology

2 companies that operate in the same segment as Aurolab (Ophthalmology) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Remidio
AI-powered portable solutions for ophthalmic screening and diagnosis are developed.
2009Bengaluru, Karnataka, IndiaUSD 25.01 MUSD 4.85 M135
Forus Health
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms
2010Bengaluru, Karnataka, IndiaUSD 18.12 MUSD 4.78 M145
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Aurolab

Auro Laboratories reports standalone net profit of Rs 1.05 crore in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
Q1 Results 14th Aug Live: Anupam Rasayan PAT up marginally, Ashok Leyland, NMDC, Alkem Lab, Bharat Dynamics, Voltas, 3M India, Cochin Shipyard, Physicswallah, Cholamandalam Fin, PTC Ind, Natco Pharma, Borosil to announce Q1 results, TMPV, Max Health lead Nifty 50 losers after Q1, Page Ind, Jubilant, LG Electronics, Honasa shares zoom - The HinduBusinessLine
Thehindubusinessline • 2 months ago
Q1 Results 14th Aug Highlights: BDL, Ashok Leyland, 3M India Q1 PAT rise y-o-y, Electrotherm, NATCO Pharma, Alkem Lab PAT decline, NMDC, Voltas, Cochin Shipyard, Physicswallah, PTC Ind, Borosil to announce Q1 results - The HinduBusinessLine
Thehindubusinessline • 2 months ago
Auro Laboratories Appoints Nitesh Bohra As CFO
Reuters • 5 months ago
Kubota Vision Secures Multiple eyeMO Device Agreements
Mpo-Mag • 2 years ago
Auro Laboratories Names Shaan Jain As CFO
Reuters • 2 years ago
Kubota Vision Announces Agreement with AUROLAB for Development, Manufacturing, Supply, and Distribution License of eyeMO
Tullahomanews • 2 years ago
Auro Laboratories Says Amit Mahipat Shah Resigned As Chief Financial Officer
Reuters • 3 years ago
Auro Laboratories Says Approved Capacity Expansion In Existing Unit
Reuters • 3 years ago
Auro Labs Standalone June 2022 Net Sales at Rs 11.19 crore
Moneycontrol • 4 years ago
Premium access

Complete news archive for Aurolab

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aurolab

Aurolab was founded in 1992 and raised its 1st funding round 28 years after it was founded.

Aurolab is headquartered in Madurai, India. It is registered at Madurai, Tamil Nadu, India.

The primary company behind Aurolab, Auro Laboratories Limited, reported revenue of ₹32.75 Cr for FY 2026, up 61% year on year.

Aurolab, an integral part of the Aravind Eye Care System manufactures high quality ophthalmic consumables such as intra-ocular lenses, surgical sutures, pharmaceutical products, surgical blades and equipments. Its products are exported to 130 countries worldwide, with focus markets like India, Africa, Latin America, Central America and Southeast Asia. The company has altered the eye-care industry by bringing down the price of the intra-ocular lens down to a tenth of international prices in the late 1990s and grown to market its products across 130 countries.

Aurolab offers Intraocular Lenses (IOLs), Diagnostic Equipment, Surgical Devices, and Ophthalmic Therapeutics.

Yes, Aurolab is publicly traded on BSE under the ticker symbol AUROLAB.

Aurolab has 1 investor. Key investors include Ideaship.

Aurolab operates through Auro Laboratories Limited.

The legal entities of Aurolab currently have 8 directors, including Kavita Vijayakant Sharma, Siddhartha Deorah, Kiran Suresh Kulkarni and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available